Literature DB >> 16763529

Depressive symptoms predict increased incidence of neuropsychiatric side effects in patients treated with efavirenz.

Larry Boly, Virginia Cafaro, Toby Dyner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16763529     DOI： 10.1097/01.qai.0000221691.61972.34

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  10 in total

1.  Discontinuation of Efavirenz in Paediatric Patients: Why do Children Switch?

Authors:  Elke Wynberg; Eleri Williams; Gareth Tudor-Williams; Hermione Lyall; Caroline Foster
Journal:  Clin Drug Investig       Date:  2018-03       Impact factor: 2.859

2.  Global HIV neurology: a comprehensive review.

Authors:  Kiran T Thakur; Alexandra Boubour; Deanna Saylor; Mitashee Das; David R Bearden; Gretchen L Birbeck
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

Review 3.  Neuropsychiatric Effects of HIV Antiviral Medications.

Authors:  Glenn J Treisman; Olivia Soudry
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

4.  Relationship of depression and catastrophizing to pain, disability, and medication adherence in patients with HIV-associated sensory neuropathy.

Authors:  Brendan P Lucey; David B Clifford; Jason Creighton; Robert R Edwards; Justin C McArthur; Jennifer Haythornthwaite
Journal:  AIDS Care       Date:  2011-08

Review 5.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

Review 6.  [Highly active antiretroviral therapy of neuro-AIDS. Side effects on the nervous system and interactions].

Authors:  I W Husstedt; D Reichelt; E Neuen-Jakob; K Hahn; F Kästner; R von Einsiedel; B Vielhaber; G Arendt; S Evers
Journal:  Nervenarzt       Date:  2009-10       Impact factor: 1.214

7.  Baseline predictors of efavirenz-containing antiretroviral regimen adverse experiences.

Authors:  Paul D Sonenthal; Bakgaki Ratshaa; Gilbert Chimbengo; Tumelo Rantleru; Thelma Ngoni; Sarah Barenbaum; Rebecca Platoff; Andrew P Steenhoff; Robert Gross
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-03-24       Impact factor: 2.890

8.  Prevalence and correlates of probable common mental disorders in a population with high prevalence of HIV in Zimbabwe.

Authors:  Dixon Chibanda; Frances Cowan; Lorna Gibson; Helen A Weiss; Crick Lund
Journal:  BMC Psychiatry       Date:  2016-02-29       Impact factor: 3.630

9.  Neuropsychiatric Adverse Events During 12 Months of Treatment With Efavirenz in Treatment-Naïve HIV-Infected Patients in China: A Prospective Cohort Study.

Authors:  Wei Hua; Sen Wang; Xi Wang; Ying Shao; Yali Wang; Jiangzhu Ye; Bin Su; Taiyi Jiang; Tong Zhang; Hao Wu; An Liu; Qunhui Li; Supriya D Mahajan; Zaicun Li; Lijun Sun; Lili Dai
Journal:  Front Psychiatry       Date:  2021-02-24       Impact factor: 4.157

Review 10.  HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz.

Authors:  Andrew Drury; Selena Gleadow-Ware; Sheila Gilfillan; Jen Ahrens
Journal:  Malawi Med J       Date:  2018-03       Impact factor: 0.875
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.